Compare Ascendis Pharma A/S (ASND) vs Hasbro, Inc. (HAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Hasbro, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Hasbro, Inc. trades at $78.76 (market cap $11.17B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Hasbro, Inc. pays a 3.55% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HAS | |
|---|---|---|
Market Cap | $17.74B | $11.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $105.88 |
52-Week Low | $163.32 | $70.95 |
Enterprise Value | $18.11B | $13.44B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Hasbro (HAS) trades at $78.96, up 2.03% today, with a bearish technical signal but bullish oscillators suggesting potential reversal. The company reported negative net income of -$322.4M in 2025 despite revenue growth to $4.7B. Recent earnings beats and a $0.70 dividend highlight operational resilience, while analyst consensus targets $104.80. News highlights include new product launches like Blooms by Play-Doh and strong performance in the Wizards segment.
Outlook: Upside exists from analyst targets and earnings momentum, but risks include high debt, margin pressure, and competitive threats. The stock presents a contrarian opportunity if operational improvements continue, though volatility near key support at $76 warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
